Apatinib as First -Line Treatment for Advanced Esophagus Cancer

Sponsor
Affiliated Hospital of North Sichuan Medical College
Study ID
NCT03542422
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Esophagus Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.

Study Details

An Exploratory study of Amapinib for patients with advanced esophagus cancer .

Key Dates

Start date
Jun 30, 2018
Status verified
Jun 2018
Primary completion
Dec 31, 2018
Completion
May 31, 2019

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.

Primary Outcome Measure

Progress free survival（PFS） [ Time Frame: 12months ]

Central Contacts